Cost-effectiveness of allopurinol and febuxostat for the management of gout

Annals of Internal Medicine

Volumn 161, Issue 9, 2014, Pages 617-626

  Jutkowitz, Eric ^a   Choi, Hyon K ^b   Pizzi, Laura T ^c   Kuntz, Karen M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRESS SYNDROME; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; GOUT; HUMAN; MEDICATION COMPLIANCE; MONOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; PROBABILITY; THEORETICAL MODEL;

ALLOPURINOL; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; GOUT; GOUT SUPPRESSANTS; HUMANS; MARKOV CHAINS; MODELS, THEORETICAL; QUALITY-ADJUSTED LIFE YEARS; THIAZOLES;

EID: 84919348617     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0227     Document Type: Article

References (39)

1. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63:3136-41. [PMID: 21800283] doi: 10.1002/art.30520
2. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431-46. [PMID: 23024028] doi:10.1002/acr.21772
3. Choi HK, Mount DB, Reginato AM; American College of Physicians. Pathogenesis of gout. Ann Intern Med. 2005;143:499-516. [PMID: 16204163]
4. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol. 2006;33:104-9. [PMID: 16267879]
5. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-24. [PMID: 16707532]
6. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al; British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46: 1372-4. [PMID: 17522099]
7. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed. 2011;39:98-123. [PMID: 22293773] doi:10.3810/psm.2011.11.1946
8. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64:229-58. [PMID: 5322938]
9. Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364:443-52. [PMID: 21288096] doi:10.1056/NEJMcp1001124
10. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-61. [PMID: 16339094]
11. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-94. [PMID: 19141576] doi: 10.1093/rheumatology/ken457
12. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-8. [PMID: 18975369] doi:10.1002/art.24209
13. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63. [PMID: 20370912] doi:10.1186/ar2978
14. Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117. [PMID: 22999027] doi: 10.1186/1477-7525-10-117
15. Moreland LW. Febuxostat-treatment for hyperuricemia and gout? [Editorial]. N Engl J Med. 2005;353:2505-7. [PMID: 16339099]
16. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29:133-40. [PMID: 21155617] doi:10.2165/11535770-000000000- 00000
17. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30. [PMID: 22679303] doi:10.1136/annrheumdis -2012-201676
18. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63:412-21. [PMID: 21279998] doi:10.1002/art.30119
19. Reinders MK, Jansen TL. Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging. 2010;5:7-18. [PMID: 20169038]
20. 2010 Red Book: Pharmacy's Fundamental Reference. 114th ed. Montvale, NJ: Thomas Reuters (Healthcare); 2010.
21. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-43. [PMID: 8453174]
22. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36:1273-82. [PMID: 19286847] doi:10.3899/jrheum.080814
23. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981;40:245-9. [PMID: 7247470]
24. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006;12:61-5. [PMID: 16601538]
25. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50:973-81. [PMID: 21228059] doi:10.1093/rheumatology/keq363
26. Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2014;15:453-63. [PMID: 23719971] doi:10.1007/s10198-013-0486-z
27. Sánchez JL, Perepérez SB, Bastida JL, Martínez MM. Cost-utility analysis applied to the treatment of burn patients in a specialized center. Arch Surg. 2007;142:50-7; discussion 57. [PMID: 17224500]
28. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B-1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012;79:1259-67. [PMID: 22955130] doi:10.1212/WNL.0b013e31826aac73
29. Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Diseaserelated and all-cause health care costs of elderly patients with gout. J Manag Care Pharm. 2008;14:164-75. [PMID: 18331118]
30. Sheils J. Harmonizing the Obama, Baucus and Wyden/Bennett health reform proposals: technical feasibility. Falls Church, VA: The Lewin Group; 2009. Accessed at www.lewin.com/-/media/Lewin/Site-Sections/Publications/Lewin AnalysisWydenBaucusFeasibility.pdf on 5 September 2014.
31. Henry J. Kaiser Family Foundation. Medicaid enrollment as a percent of total population, FY2010. Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2010. Accessed at http://kff.org/medicaid/state-indicator/medicaid -enrollment-as-a-of-pop on 24 March 2014.
32. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine.New York: Oxford Univ Pr; 1996.
33. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. New York: Oxford Univ Pr; 2006.
34. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-34. [PMID: 16835972]
35. National Institute for Health and Care Excellence. Febuxostat for the Management of Hyperuricaemia in People with Gout: NICE technology appraisals [TA164]. London: National Institute for Health and Care Excellence; 2008. Accessed at www.nice.org.uk/guidance/TA164 on 9 September 2014.
36. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154:174-80. [PMID: 21282697] doi: 10.7326/0003-4819-154-3-201102010-00007
37. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349-56. [PMID: 18362813] doi:10.1097 /MLR.0b013e31815c31a7
38. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995;22:908-14. [PMID: 8587081]
39. Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. Evid Based Med. 2012;17:105-8. [PMID: 22345034] doi:10.1136 /ebmed-2011-100065